Editor’s Pick: Paradigm Shift in the Management of Gynaecological Cancers - European Medical Journal

Editor’s Pick: Paradigm Shift in the Management of Gynaecological Cancers

Oncology
Download PDF
Authors:
Katelijn Sap, *Philippe Van Trappen
Disclosure:

No potential conflict of interest.

Received:
03.12.14
Accepted:
07.01.15
Citation:
EMJ Oncol. ;3[1]:12-18. DOI/10.33590/emjoncol/10312687. https://doi.org/10.33590/emjoncol/10312687.
Keywords:
Ovarian cancer, endometrial cancer, cervical cancer, positron emission tomography (PET), magnetic resonance imaging (MRI), ultra-radical surgery, robot, sentinel lymph node, molecular therapy.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

In this review we highlight novel aspects of diagnostic imaging in gynaecological cancers, the paradigm shift in the surgical management of certain female pelvic cancers, as well as potential new molecular targeted therapies. In the last decade, ultra-radical surgery has been shown to increase survival in  advanced ovarian cancer (OVC) when extended surgical procedures are included during primary  cytoreductive surgery or at interval debulking procedures after neoadjuvant chemotherapy. In cervical  cancer (CVC) and endometrial cancer (EMC) endoscopic (laparoscopic or robotic) operations have been shown to significantly reduce the morbidity without altering the cancer-related survival. Although the  sentinel lymph node concept is already established in early-stage vulvar cancer, its diagnostic accuracy in  EMC and CVC is still under debate. Novel molecular targeted therapies including blocking agents against new blood vessel formation (anti-angiogenesis) and polyadenosine diphosphate ribose polymerase inhibitors have been shown to prolong the progression-free survival in advanced OVC. Other molecular therapies, single or combined, are under investigation in OVC and EMC.

Please view the full content in the pdf above.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?